Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2003 1
2005 1
2006 2
2007 4
2008 9
2009 12
2010 2
2011 2
2013 4
2014 5
2015 10
2016 7
2017 5
2018 7
2019 18
2020 23
2021 27
2022 22
2023 27
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

171 results

Results by year

Filters applied: . Clear all
Page 1
Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study.
Goetz MP, Cicin I, Testa L, Tolaney SM, Huober J, Guarneri V, Johnston SRD, Martin M, Rastogi P, Harbeck N, Shahir A, Wei R, André V, Rugo HS, O'Shaughnessy J. Goetz MP, et al. Among authors: cicin i. NPJ Breast Cancer. 2024 Apr 26;10(1):34. doi: 10.1038/s41523-024-00639-1. NPJ Breast Cancer. 2024. PMID: 38671001 Free PMC article.
RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer.
Spigel DR, Dowlati A, Chen Y, Navarro A, Yang JC, Stojanovic G, Jove M, Rich P, Andric ZG, Wu YL, Rudin CM, Chen H, Zhang L, Yeung S, Benzaghou F, Paz-Ares L, Bunn PA; RESILIENT Trial Investigators. Spigel DR, et al. J Clin Oncol. 2024 Apr 22:JCO2302110. doi: 10.1200/JCO.23.02110. Online ahead of print. J Clin Oncol. 2024. PMID: 38648575
Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG).
Yasar HA, Aktas BY, Ucar G, Goksu SS, Bilgetekin I, Cakar B, Sakin A, Ates O, Basoglu T, Arslan C, Demiray AG, Paydas S, Cicin I, Sendur MAN, Karadurmus N, Kosku H, Uner A, Yumuk PF, Utkan G, Kefeli U, Tanriverdi O, Cinkir H, Gumusay O, Turhal NS, Menekse S, Kut E, Beypinar I, Sakalar T, Demir H, Yekeduz E, Kilickap S, Erman M, Urun Y. Yasar HA, et al. Among authors: cicin i. Clin Genitourin Cancer. 2024 Mar 15;22(3):102077. doi: 10.1016/j.clgc.2024.102077. Online ahead of print. Clin Genitourin Cancer. 2024. PMID: 38626660
Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC.
Yildirim ME, Karadurmuş N, Ökten İN, Türk HM, Urakçı Z, Arslan Ç, Çelik S, Dane F, Şendur MAN, Bilir C, Karabulut B, Cicin İ, Çubukçu E, Karaca M, Ozcelik M, Artaç M, Tanrikulu E, Alacacioglu A, Açıkgöz Ö, Öven B, Geredeli Ç, Çil T, Harputluoğlu H, Kefeli U, Bozkurt O, Tural D, Sakin A, Yalçın Ş, Gumus M. Yildirim ME, et al. Among authors: cicin i. J Oncol Pharm Pract. 2024 Apr 13:10781552241241004. doi: 10.1177/10781552241241004. Online ahead of print. J Oncol Pharm Pract. 2024. PMID: 38613329
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano D, Fornarini G, Li JR, Gümüş M, Mar N, Loriot Y, Fléchon A, Duran I, Drakaki A, Narayanan S, Yu X, Gorla S, Homet Moreno B, van der Heijden MS; EV-302 Trial Investigators. Powles T, et al. N Engl J Med. 2024 Mar 7;390(10):875-888. doi: 10.1056/NEJMoa2312117. N Engl J Med. 2024. PMID: 38446675 Clinical Trial.
The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing.
Köstek O, Demirel A, Hacıoğlu MB, Tastekin D, Karabulut S, Gündogdu A, Sever N, Ayhan M, Çelebi A, Majidova N, Yaşar A, Ağyol Y, Erel P, Kocaaslan E, Güren AK, Arıkan R, Isık S, Ercelep O, Goksu SS, Alandag C, Bilgetekin İ, Caner B, Sahin AB, Gulmez A, Akagunduz B, Kose F, Kaplan MA, Dogan E, Sakalar T, Guven DC, Gurbuz M, Ergun Y, Karaagac M, Turker S, Ozkul O, Yıldız B, Sahin S, Demiray AG, Sari M, Erdogan B, Hacıbekiroglu İ, Çakmak Öksüzoğlu ÖB, Kilickap S, Bilici A, Bayoglu İV, Topaloglu S, Cicin İ. Köstek O, et al. Among authors: cicin i. J Chemother. 2024 Jan 23:1-9. doi: 10.1080/1120009X.2024.2305066. Online ahead of print. J Chemother. 2024. PMID: 38263804
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.
Rastogi P, O'Shaughnessy J, Martin M, Boyle F, Cortes J, Rugo HS, Goetz MP, Hamilton EP, Huang CS, Senkus E, Tryakin A, Cicin I, Testa L, Neven P, Huober J, Shao Z, Wei R, André V, Munoz M, San Antonio B, Shahir A, Harbeck N, Johnston S. Rastogi P, et al. Among authors: cicin i. J Clin Oncol. 2024 Mar 20;42(9):987-993. doi: 10.1200/JCO.23.01994. Epub 2024 Jan 9. J Clin Oncol. 2024. PMID: 38194616 Free PMC article.
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Masi G, Kwiatkowski M, Lim HY, Kim JH, Breder V, Kumada H, Cheng AL, Galle PR, Kaneko S, Wang A, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS; LEAP-002 Investigators. Llovet JM, et al. Lancet Oncol. 2023 Dec;24(12):1399-1410. doi: 10.1016/S1470-2045(23)00469-2. Lancet Oncol. 2023. PMID: 38039993 Clinical Trial.
171 results